Sanofi Gets Double Blow for MS Drug Tolebrutinib

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

Sanofi shares fall 6% after double setback for MS drug tolebrutinib

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.The post Sanofi shares fall 6% after double setback for MS drug tolebrutinib appeared first on Clinical Trials Arena.

Sanofi shares fall 6% after double setback for MS drug tolebrutinib - Pharmaceutical Technology

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Re…